Design of fusion inhibitors to block measles host-to-host infection

设计融合抑制剂来阻止麻疹宿主间感染

基本信息

  • 批准号:
    10457081
  • 负责人:
  • 金额:
    $ 56.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-08-09 至 2023-07-31
  • 项目状态:
    已结题

项目摘要

Measles (MeV) causes disease worldwide despite efforts towards eradication by vaccine, largely because it is spread so readily between people. Acute MeV infection causes immune amnesia, resulting in increased susceptibility to other infectious diseases. In addition, rare but severe neurological complications can develop several years after measles due to persistent MeV infection of the central nervous system. People with impaired cellular immunity are at increased risk of developing severe measles, but often cannot be vaccinated since the vaccine virus itself can lead to fatal illness. There is no specific therapy for acute or persistent MeV manifestations. A successful vaccination campaign could have eradicated MeV more than 20 years ago. As today, mainly due to social issue (e.g., antivaxxer movement), eradication is not in sight. The recent resurgence of measles in the U.S. highlights the need of effective measure to prevent host-to-host transmission at the moment of the outbreak surge. We have applied the results of fundamental research to develop a new antiviral strategy for MeV, based on inhibiting membrane fusion during MeV entry. This application will test whether our antiviral approach prevents inter-host transmission and therefore fill this medical demand. Our strategy is based MeV fusion inhibitors (i.e., lipid conjugated peptides) that self-assemble in stable nanoparticles until they reach the target cells were, they integrated into the cell membrane. We have recently shown that this strategy works effectively for SARS-CoV-2. We propose to chemical engineer these inhibitors to optimize 1) the antiviral potency, 2) the conditions under which the peptides self-assemble, 3) the insertion on the target cell membrane, and 5) in vivo biodistribution. Our work will be tested in vitro, ex vivo, and in vivo using a natural model of morbillivirus infection (Canine Distemper Virus -CDV- in Ferrets). 1. To use protein engineering to optimize the self-assembling properties and antiviral potency of HRC-peptide fusion inhibitors. 2. To evaluate the protection afforded by HRC peptide fusion inhibitors against CDV infection in vivo and provide proof of concept for pre-clinical development.
麻疹(MeV)在世界范围内引起疾病,尽管人们努力根除麻疹, 疫苗,主要是因为它很容易在人与人之间传播。急性MeV感染 导致免疫健忘症,从而增加对其他感染性疾病的易感性。 疾病此外,罕见但严重的神经系统并发症可能会发展成几种 由于中枢神经系统的持续MeV感染,麻疹后10年。 细胞免疫力受损的人患严重的 麻疹,但往往不能接种疫苗,因为疫苗病毒本身可导致致命的 病对于急性或持续性MeV表现没有特异性治疗。一 成功的疫苗接种运动可以在20多年前消除MeV。 今天,主要是由于社会问题(例如,antivaxxer运动),根除不是在 视线最近在美国麻疹的复苏强调了有效的预防措施的必要性。 在疫情激增时采取措施防止宿主到宿主的传播。 我们已经应用基础研究的结果来开发新的抗病毒策略 对于MeV,基于在MeV进入期间抑制膜融合。此应用程序将 测试我们的抗病毒方法是否可以防止宿主间的传播, 医疗需求。我们的策略是基于MeV融合抑制剂(即,脂质缀合 肽)在稳定的纳米颗粒中自组装,直到它们到达靶细胞 它们被整合到细胞膜中。 我们最近证明,这种策略对SARS-CoV-2有效。 我们建议对这些抑制剂进行化学工程改造,以优化1)抗病毒效力,2) 肽自组装的条件,3)插入靶细胞 膜,和5)体内生物分布。 我们的工作将在体外,离体,和使用麻疹病毒的天然模型在体内进行测试 感染(犬瘟热病毒-CDV-在雪貂)。 1.利用蛋白质工程优化自组装特性, HRC-肽融合抑制剂的抗病毒功效。 2.为了评估HRC肽融合抑制剂提供的保护, CDV体内感染,并为临床前开发提供概念验证。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Matteo Porotto其他文献

Matteo Porotto的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Matteo Porotto', 18)}}的其他基金

Design of fusion inhibitors to block measles host-to-host infection
设计融合抑制剂来阻止麻疹宿主间感染
  • 批准号:
    10753711
  • 财政年份:
    2023
  • 资助金额:
    $ 56.12万
  • 项目类别:
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2
阻止 SARS-CoV-2 宿主间传播的融合抑制剂
  • 批准号:
    10457959
  • 财政年份:
    2021
  • 资助金额:
    $ 56.12万
  • 项目类别:
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2
阻止 SARS-CoV-2 宿主间传播的融合抑制剂
  • 批准号:
    10668973
  • 财政年份:
    2021
  • 资助金额:
    $ 56.12万
  • 项目类别:
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2
阻止 SARS-CoV-2 宿主间传播的融合抑制剂
  • 批准号:
    10237600
  • 财政年份:
    2021
  • 资助金额:
    $ 56.12万
  • 项目类别:
Small molecules to block measles spreading in the central nervous system
小分子阻止麻疹在中枢神经系统中传播
  • 批准号:
    9986209
  • 财政年份:
    2019
  • 资助金额:
    $ 56.12万
  • 项目类别:
Development of therapeutic fusion inhibitor peptides for Measles encephalitis
开发治疗麻疹脑炎的融合抑制肽
  • 批准号:
    10414909
  • 财政年份:
    2018
  • 资助金额:
    $ 56.12万
  • 项目类别:
Development of therapeutic fusion inhibitor peptides for Measles encephalitis
开发治疗麻疹脑炎的融合抑制肽
  • 批准号:
    10178126
  • 财政年份:
    2018
  • 资助金额:
    $ 56.12万
  • 项目类别:
Development of therapeutic fusion inhibitor peptides for Measles encephalitis
开发治疗麻疹脑炎的融合抑制肽
  • 批准号:
    9973101
  • 财政年份:
    2018
  • 资助金额:
    $ 56.12万
  • 项目类别:
Self-assembling nanoparticles for intranasal delivery of influenza fusion inhibitors
用于鼻内递送流感融合抑制剂的自组装纳米颗粒
  • 批准号:
    9441694
  • 财政年份:
    2016
  • 资助金额:
    $ 56.12万
  • 项目类别:
Development of novel endosome-targeted Ebola virus entry inhibitors as antiviral agents
开发新型内体靶向埃博拉病毒进入抑制剂作为抗病毒药物
  • 批准号:
    9431045
  • 财政年份:
    2016
  • 资助金额:
    $ 56.12万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 56.12万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 56.12万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 56.12万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 56.12万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 56.12万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 56.12万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 56.12万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 56.12万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 56.12万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 56.12万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了